Companies are investing heavily in complex injectables, respiratory therapies and biosimilars to improve margins and diversify portfolios.
Sun Pharmaceutical Industries reported a 27 per cent year-on-year increase in consolidated net profit to 2,894.7 crore for Q1FY27, with revenue growing 10 per cent to 15,299.8 crore, driven by strong performance in India and innovative medicines.
Torrent Pharma has emerged as a top sectoral pick for brokerages, driven by healthy growth in India revenues and improved gross margins, leading to a 44 per cent stock return over the past year.
Sun Pharmaceutical Industries reported strong consolidated numbers for Q4 FY26, with net profit rising 26 per cent year-on-year to 2,714 crore, despite continued weakness in its US generics business. Growth in innovative medicines and increased R&D investments are helping to offset these pressures.
Indian pharmaceutical companies are strategically increasing investments in the US market, focusing on specialty drugs, complex generics, respiratory products, and local manufacturing, despite a nearly 10 per cent fall in exports to the US in FY26 due to pricing pressure and competition in traditional generics.
The World Health Organization has requested information from the Indian government regarding the alleged supply of spurious oxytocin injections linked to the deaths of five women in Kota hospitals. This comes after regulatory action, including the cancellation of manufacturing licenses for Jackson Laboratories units, following joint inspections by drug control bodies. The government is investigating the matter, emphasising a zero-tolerance approach to quality violations.
Piramal Pharma anticipates a significant turnaround in financial year 2026-27 (FY27), projecting early-to-mid teens revenue expansion and a sharp improvement in profitability, driven by improved business momentum, new product acquisitions, and structural tailwinds.
The Maharashtra Food and Drug Administration (FDA) has cancelled the licences of 10 Ayurvedic drug manufacturing units and issued show-cause notices to 135 others following inspections that revealed serious violations including unhygienic conditions, lack of technical staff, and inadequate testing protocols.
Odisha-based Serendipity Space successfully demonstrated drug crystallisation processes on a satellite prototype in a near-space mission. This breakthrough aims to enable pharmaceutical manufacturing in low Earth orbit, leveraging microgravity to create superior drug crystal structures for enhanced solubility, stability, and effectiveness. The mission tested core technologies, including an autonomous pharmaceutical factory, and was inspired by advancements made on the International Space Station.
Sun Pharmaceutical Industries Ltd has announced its acquisition of US-based Organon & Co in an all-cash deal valued at an enterprise valuation of USD 11.75 billion, aiming to become a top 25 global pharmaceutical company.
India's 10 most valuable families had a combined valuation of Rs 70.5 trillion.
Sun Pharmaceutical Industries' Executive Chairman Dilip Shanghvi described the USD 11.75 billion acquisition of US-based Organon & Co as both a "happy" and "bit anxious" moment, acknowledging the significant debt required to fund the large transaction.
Indian benchmark indices Sensex and Nifty rebounded in early trade after three days of decline, driven by a rally in Sun Pharma following its USD 11.75 billion acquisition of US-based Organon & Co, alongside a positive trend in global equity markets.
Indian benchmark indices, Sensex and Nifty, experienced declines in early trade due to a surge in crude oil prices and significant selling pressure on bank stocks, impacting overall investor sentiment. Track Sensex, Nifty on July 22.
Indian stock market benchmark indices, Sensex and Nifty, saw significant gains in early trade, driven by a sharp decline in crude oil prices and easing geopolitical tensions, alongside renewed foreign fund inflows.
US President Donald Trump announced steep tariffs on imported generic medicines, effective from August 2028, with the aim of boosting domestic pharmaceutical production. This policy, which includes a phased increase in tariffs up to 200 per cent, could significantly impact India, a major global supplier of generic drugs to the US market.
Indian benchmark stock indices, Sensex and Nifty, extended their winning streak to a fourth day, with Nifty surging 1.60 per cent, driven by a sharp decline in crude oil prices and renewed foreign fund inflows.
Indian benchmark indices, Sensex and Nifty, opened higher on Friday, primarily driven by a significant surge in Bajaj Finance shares following its strong Q1 FY27 earnings report, coupled with continued foreign fund inflows and a dip in crude oil prices. Track Sensex, Nifty on July 31.
Indian benchmark indices, Sensex and Nifty, opened in positive territory, primarily driven by a strong performance in IT stocks, sustained foreign fund inflows, and a dip in global crude oil prices, despite a hawkish stance from the US Federal Reserve. Track Sensex, Nifty on July 30.
India's outward foreign direct investment (FDI) plummeted by 47.9 per cent year-on-year to $3 billion in June 2026, according to the Reserve Bank of India (RBI), with declines across equity, debt, and guarantee commitments.
Indian benchmark equity indices closed higher on Thursday, with the Sensex gaining 273.55 points to 77,928.15 and the Nifty rising 66.95 points to 24,317.15, driven by bargain hunting and short-covering in IT and auto sectors.
Sun Pharmaceutical Industries' acquisition of US-based Organon & Co. for $11.75 billion, the largest overseas acquisition by an Indian pharma company, has been met with mixed reactions from brokerages, who see strategic entry into women's health and biosimilars but also flag potential integration challenges and debt concerns.
Congress MP from Jalandhar, Charanjit Singh Channi, was conspicuous by his absence when party leader Rahul Gandhi spoke in a debate in the Lok Sabha on Wednesday, bringing to the fore the recent rift within the party's state unit.
Homegrown pharma major Cipla Ltd reported a 39 per cent decline in consolidated net profit to Rs 785.55 crore in the first quarter ended June 2026, primarily due to a dip in sales in the North American market and higher expenses.
At the heart of this debate is Section 3(d) of the Patents Act, a safeguard designed to prevent drugmakers from extending monopoly protection through trivial modifications to existing medicines.
Indian benchmark indices Sensex and Nifty experienced a significant decline in early trade, with the Sensex falling over 500 points and the Nifty over 150 points, as Brent crude oil prices surged past USD 100 per barrel due to escalating geopolitical tensions in the West Asia. track sensex, Nifty on July 24.
Indian benchmark indices Sensex and Nifty experienced a significant decline in early trade, driven by renewed tensions between the US and Iran and a subsequent spike in global crude oil prices, creating uncertainty in the market. Track Sensex, Nifty on July 8.
Indian benchmark indices Sensex and Nifty experienced a downturn in early trade, primarily influenced by a dip in HDFC Bank shares, persistent outflows from foreign funds, and escalating geopolitical tensions between the US and Iran. Track Sensex, Nifty performance.
Indian benchmark indices Sensex and Nifty rallied in early trade, primarily driven by strong buying in IT stocks after Tech Mahindra reported a significant 28.4 per cent rise in its consolidated net profit for the June quarter.
Indian benchmark indices Sensex and Nifty rebounded in early trade on Thursday, recovering from a sharp fall in the previous session, driven by foreign fund inflows and buying in key blue-chip stocks. Track Sensex, Nifty on July 9, 2026.
Dr Reddy's Laboratories reported a 68.7 per cent year-on-year decline in consolidated net profit to Rs 443.5 crore in Q1 FY27, primarily due to the end of its lenalidomide sales agreement, a Rs 240-crore provision for semaglutide API inventory quality issues, and elevated freight costs.
India's pharmaceutical industry is experiencing increased bulk drug prices, particularly for APIs from China, following the escalation of the West Asia crisis in March. While current inventories provide a temporary buffer, concerns are mounting over the availability of key solvents and feedstocks, potentially leading to manufacturing disruptions and shortages in specific drug categories.
Indian benchmark indices, Sensex and Nifty, experienced a significant downturn as escalating tensions in West Asia led to a sharp surge in crude oil prices, coupled with fresh foreign fund outflows and a weakening rupee.
Indian stock markets witnessed a significant rally, with the Sensex climbing 964.58 points and the Nifty reaching 24,330, driven by strong buying in blue-chip stocks, particularly in the IT and banking sectors, amidst optimism over Q1 earnings and a shift towards large-cap investments.
Indian benchmark indices Sensex and Nifty continued their upward trend for a second consecutive day, with the Sensex gaining over 800 points, driven by strong performances from heavyweights like Reliance Industries, ICICI Bank, and HDFC Bank, alongside positive cues from easing crude oil prices and robust IT sector earnings.
Indian benchmark indices, Sensex and Nifty, experienced subdued trading and turned flat on Tuesday as investors engaged in profit-booking following a recent rally, compounded by weak Asian market trends and fresh foreign fund outflows.
Indian benchmark indices Sensex and Nifty surged in early trade, with the Sensex jumping nearly 700 points, primarily driven by strong buying in IT stocks following TCS's positive June-quarter results and optimistic demand outlook. Track Sensex, Nifty on July 10, 2026.
Indian benchmark indices, Sensex and Nifty, staged a moderate rebound after a significant correction in the previous session, driven by foreign fund inflows and a largely positive trend in global markets, though geopolitical tensions between the US and Iran continued to foster caution.
Danish pharma major Novo Nordisk has launched 'Awiqli' in India, a once-weekly basal insulin injection for adults with diabetes, aiming to simplify treatment and reduce the burden of daily injections.
The Maharashtra Food and Drug Administration (FDA) conducted three separate operations in Pune and Kolhapur, seizing illegal medicines worth over Rs 24 lakh. Actions included seizing allopathic medicines from an unlicensed firm and prescription drugs with improper promotional packaging, with the FDA vowing strict action against violators.
